Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Compound monograph · §3

GHRP-6 — clinical evidence

Assessed outcomes with certainty ratings, contributing trials and the reasoning for each rating.

Document identifier
CEI-MN-027/3
Series
Compound monograph
Version
4.0
Published
21 Nov 2024
Last reviewed
21 Sep 2025
Next review
21 Sep 2027
Identifier
10.71829/cei.mono.27
Certainty
Very low
Cycle
2024 Q4

§3Clinical evidence

Assessed outcomes for GHRP-6Point estimates with confidence intervals for each contributing study, plotted against the line of no effect.0.00.20.40.60.8Standardised direction and relative magnitude of the recorded effectIndicationEffect as recordedGH axis1 trial · LowDose-dependent acute growth-hormone…Wound healing0 trials · Very lowNo randomised human evidence identified
Moderate or high certaintyLow or very low certainty
Figure 3. Illustrative. Assessed outcomes plotted on a common standardised axis so that direction and relative magnitude can be compared at a glance. The estimates are not on a common natural scale and the intervals are the Institute's standardised representation of the reported precision, not the published confidence intervals. Published intervals appear in the per-indication extracts and in the text below.

§3.1Growth hormone deficiency and growth-hormone secretagogue pharmacology

Anchor outcome. Peak stimulated growth hormone.

Effect as recorded. Dose-dependent acute growth-hormone release with attenuation on repeated administration; pharmacodynamic.[1,2]

Certainty. Low certainty Historical human pharmacodynamic data exist. No therapeutic outcome trial does.

Contributing trials. GHRP6-PH1-GH. Full structured abstracts are published for each.

Full evidence extract for growth hormone deficiency and growth-hormone secretagogue pharmacology · Indication assessment

§3.2Cutaneous wound healing and tissue repair

Anchor outcome. Time to complete closure.

Effect as recorded. No randomised human evidence identified; —.[2,3]

Certainty. Very low certainty Preclinical cytoprotection studies exist; no human trial does.

Contributing trials. None identified. The rating reflects an absence of controlled evidence rather than conflicting evidence.

Full evidence extract for cutaneous wound healing and tissue repair · Indication assessment

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

  1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology 1998;139(5):552–561. doi:10.1530/eje.0.1390552 · PMID 9849822
  2. Thevis M, Thomas A, Schänzer W. Detecting peptidic drugs, drug candidates and analogs in sports doping: current status and future directions. Expert Review of Proteomics 2019;11(6):663–673. doi:10.1586/14789450.2014.965158
  3. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.